InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar)

Deng R, Tian R, Li X, et al. ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis. iScience. 2024,27(4):109533. doi: 10.1016/j.isci.2024.109533

Lee DH, Ahn H, Sim HI, et al. A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity. J Exp Clin Cancer Res. 2023,42(1):272. doi: 10.1186/s13046-023-02840-9

Sun R, Meng Z, Lee H, et al. ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation. Cell Chem Biol. 2023,30(7):739-752.e8. doi: 10.1016/j.chembiol.2023.05.010

Zhao Y, Caron C, Chan YY, et al. cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8(+) T cell function and anti-tumor immunity. Immunity. 2023,56(6):1187-1203.e12. doi: 10.1016/j.immuni.2023.04.005